Agilent Technologies Inc (NYSE:A) – Svb Leerink reduced their FY2019 earnings per share (EPS) estimates for Agilent Technologies in a note issued to investors on Wednesday, May 15th. Svb Leerink analyst P. Souda now expects that the medical research company will post earnings of $3.04 per share for the year, down from their prior forecast of $3.07. Svb Leerink also issued estimates for Agilent Technologies’ Q2 2020 earnings at $0.78 EPS, Q3 2020 earnings at $0.83 EPS and FY2020 earnings at $3.36 EPS.
A has been the subject of a number of other reports. Deutsche Bank reiterated a “buy” rating and issued a $90.00 target price on shares of Agilent Technologies in a report on Thursday, February 21st. Robert W. Baird reiterated a “buy” rating and issued a $82.00 target price (up from $77.00) on shares of Agilent Technologies in a report on Wednesday, February 20th. Needham & Company LLC reiterated a “buy” rating and issued a $88.00 target price (up from $77.00) on shares of Agilent Technologies in a report on Monday, February 25th. Zacks Investment Research lowered Agilent Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. Finally, Barclays lifted their target price on Agilent Technologies from $80.00 to $83.00 and gave the company an “overweight” rating in a report on Thursday, February 21st. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Agilent Technologies has an average rating of “Buy” and an average target price of $86.58.
NYSE:A opened at $69.11 on Friday. The firm has a market capitalization of $22.00 billion, a P/E ratio of 24.77, a P/E/G ratio of 1.93 and a beta of 1.33. Agilent Technologies has a 12-month low of $60.42 and a 12-month high of $82.27. The company has a quick ratio of 2.79, a current ratio of 3.41 and a debt-to-equity ratio of 0.35.
Agilent Technologies (NYSE:A) last released its earnings results on Tuesday, May 14th. The medical research company reported $0.71 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.72 by ($0.01). The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Agilent Technologies had a net margin of 22.25% and a return on equity of 19.71%. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter last year, the business posted $0.65 earnings per share.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd were issued a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend was Monday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is 23.66%.
In other Agilent Technologies news, Director Paul N. Clark sold 2,823 shares of Agilent Technologies stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $80.31, for a total transaction of $226,715.13. Following the completion of the sale, the director now directly owns 88,857 shares of the company’s stock, valued at approximately $7,136,105.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dominique Grau sold 7,711 shares of Agilent Technologies stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $80.00, for a total value of $616,880.00. Following the sale, the insider now directly owns 102,196 shares of the company’s stock, valued at $8,175,680. The disclosure for this sale can be found here. Insiders have sold a total of 48,583 shares of company stock valued at $3,855,924 over the last ninety days.
A number of hedge funds and other institutional investors have recently made changes to their positions in A. Vanguard Group Inc increased its position in shares of Agilent Technologies by 0.8% during the third quarter. Vanguard Group Inc now owns 24,155,483 shares of the medical research company’s stock worth $1,703,929,000 after purchasing an additional 194,607 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Agilent Technologies by 0.6% during the first quarter. Wellington Management Group LLP now owns 8,435,949 shares of the medical research company’s stock worth $678,083,000 after purchasing an additional 51,076 shares in the last quarter. Artisan Partners Limited Partnership increased its position in shares of Agilent Technologies by 0.6% during the first quarter. Artisan Partners Limited Partnership now owns 5,858,087 shares of the medical research company’s stock worth $470,873,000 after purchasing an additional 36,359 shares in the last quarter. FMR LLC increased its position in shares of Agilent Technologies by 2.9% during the first quarter. FMR LLC now owns 5,635,232 shares of the medical research company’s stock worth $452,960,000 after purchasing an additional 159,653 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Agilent Technologies by 20.6% during the first quarter. American Century Companies Inc. now owns 4,928,415 shares of the medical research company’s stock worth $396,146,000 after purchasing an additional 840,850 shares in the last quarter.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Featured Article: Price-Sales Ratio
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.